What is HCG?
Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.
Biological role or research focus
Gonadal hormone and fertility research.
Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims.
Names you may encounter
Human chorionic gonadotropin · hCG
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Glycoprotein hormone
- Research focus
- Gonadal hormone and fertility research
- Featured evidence
- Human randomized comparative trial
- Source check
- October 4, 2026
Quick answers
- Is HCG FDA approved?
- Yes. Pregnyl (BLA 017692) and chorionic gonadotropin for injection for prepubertal cryptorchidism, hypogonadotropic hypogonadism in males, and ovulation induction. Source ↗
- Is HCG safe?
- Approved fertility and hormone drug; main risks are ovarian hyperstimulation, multiple births and blood clots, and its label states it does not help with weight loss. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is HCG banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
- Has the FDA taken action over HCG?
- Yes. Our records list 1 FDA action naming it, most recently on July 13, 2020: FDA consumer warning that over-the-counter HCG weight-loss products are illegal and unproven; HCG is approved only as a prescription drug for other uses. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| HCG and clomiphene in male hypogonadism (2018) | Human randomized comparative trial | Men with hypogonadism who wished to preserve fertility. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized comparative trial · 2018
HCG and clomiphene in male hypogonadism
What did this publication test, and what did it find?
- Population / model
- Men with hypogonadism who wished to preserve fertility.
- Study design
- Randomized three-month comparison of HCG, clomiphene, and their combination.
- Main finding
- Testosterone increased in all three groups, without a significant between-group difference. The combined group had a greater reported improvement in symptom scores.
- Limits & context
- Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
21 registered studies name HCG as an intervention among the 100 most recently updated of 412 search results; 6 are recruiting or under way, 2 have not started recruiting yet, 10 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 21 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Hyperglycosylated hCG. ↗
Placenta · 2007 Oct · Journal Article, Review
Total hCG tests. ↗
Clinica chimica acta; international journal of clinical chemistry · 2011 Nov 20 · Journal Article
Hyperglycosylated hCG and pregnancy failures. ↗
Journal of reproductive immunology · 2012 Mar · Journal Article
Familial HCG syndrome. ↗
Journal of reproductive immunology · 2012 Jan · Case Reports, Journal Article
Risks & interactions
Approved fertility and hormone drug; main risks are ovarian hyperstimulation, multiple births and blood clots, and its label states it does not help with weight loss.
This older label is brief, with no detailed trial safety data or drug interaction section. It states hCG has not been shown to be effective for obesity or to increase weight loss beyond calorie restriction.
Take extra care with: Cancer, now or in the pastPregnancy or breastfeeding
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Children with early (precocious) puberty
- People with prostate cancer or other androgen-dependent tumors
- Past allergic reaction to hCG
Serious risks
- Ovarian hyperstimulation syndrome: sudden ovary enlargement with fluid in the abdomen or chest
- Ruptured ovarian cysts with internal bleeding
- Multiple pregnancies
- Arterial blood clots (thromboembolism)
- Anaphylaxis and other allergic reactions
- Early puberty in children; possible fetal harm in pregnancy, based on mouse studies
Common side effects
- headache
- irritability
- restlessness
- depression
- fatigue
- swelling (edema)
- breast enlargement in males
- injection-site pain
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Chorionic gonadotropin prescribing information ↗
Safety & what remains unknown
Hormonal interventions require diagnosis-specific monitoring. This comparison cannot establish the suitability of an unverified research preparation.
Evidence boundaries
Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims.
Regulatory status
- U.S. FDA approval
- Approved
Pregnyl (BLA 017692) and chorionic gonadotropin for injection for prepubertal cryptorchidism, hypogonadotropic hypogonadism in males, and ovulation induction. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly ("chorionic gonadotrophin (CG)"); prohibited in males. source
FDA actions
- FDA consumer warning that over-the-counter HCG weight-loss products are illegal and unproven; HCG is approved only as a prescription drug for other uses. (2020-07-13) source
Other notes
- Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as hCG were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This is a reproductive-endocrinology profile. Fertility treatment depends on the underlying diagnosis and exact medicine, rather than general gym or recovery protocols.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
HCG acts through luteinizing-hormone receptor signaling. An increase in testosterone is an endocrine outcome and does not, by itself, prove conception or a live birth.
Questions worth asking
- Does a testosterone increase prove improved fertility?
- What material, population, and route were actually studied?
- Short-term hormonal and symptom outcomes should not be converted into pregnancy, live-birth, or long-term fertility claims.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does a testosterone increase prove improved fertility?
No. Hormone concentrations and symptoms are different endpoints from sperm quality, conception, and live birth.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
